Study drug for advanced solid tumors in adults
Part of Cancer clinical trials.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign informed consent and be at least 18 years old
- Have advanced solid tumor cancer that has progressed or can’t be treated with standard therapy
- Be expected to live at least 3 months and be well enough to do most daily activities (ECOG 0–1)
- For dose-finding: have at least one spot doctors can measure on scans (evaluable/measurable lesion)
- For the larger tumor group in the later phase: your tumor must match certain gene/drug targets (like NF2, YAP/TAZ fusion, or LATS1/2 changes)
- You must not have had a prior TEAD inhibitor, and you may need enough time after past cancer treatments (washout)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This Phase 1 trial tests BPI-371153, a new treatment, in people with advanced solid tumors or relapsed or refractory lymphoma whose cancer has returned or progressed after standard care. The goal is to find a safe dose and learn whether it can shrink tumors or help control disease.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.